Open AccessWhat are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?
Author(s) -
Ю. Ю. Киселёв,
V.M. Tsvetov Tsvetov,
К. Б. Мирзаев,
Д. А. Сычёв
Publication year - 2020
Publication title -
kačestvennaâ kliničeskaâ praktika
Language(s) - English
Resource type - Journals
eISSN - 2618-8473
pISSN - 2588-0519
DOI - 10.37489/2588-0519-2020-s4-47-49
Subject(s) - lopinavir , ritonavir , hydroxychloroquine , lopinavir/ritonavir , medicine , cardiotoxicity , qt interval , covid-19 , intensive care medicine , pharmacology , virology , human immunodeficiency virus (hiv) , toxicity , viral load , antiretroviral therapy , disease , infectious disease (medical specialty)
Some guidelines describe combined use of hydroxychloroquine and lopinavir/ritonavir as one of the treatment alternatives for severe COVID-19, yet this treatment is not preferable. It requires careful consideration of possible interactions with other drugs, monitoring of cardiotoxicity (including QT-interval measurement), and hepatotoxicity (measurement of ASAT/ ALAT).